Final guidance on the drug’s use to treat patients with severe eosinophilic asthma on the NHS has now been published
News
Patients gain early access to Pfizer’s atopic dermatitis drug
The MHRA has issued a positive scientific opinion for abrocitinib allowing its use via the early access to medicines scheme (EAMS)
New analysis backs safety, efficacy of AZ/Oxford COVID-19 jab
The data show 100% protection against severe disease, hospitalisation and death, greater vaccine efficacy with an inter-dose interval of 12 weeks or more, and the potential for reduced asymptomatic transmission
Novo Nordisk’s Sogroya moves closer towards EU approval
CHMP recommended marketing authorisation for human growth hormone therapy
EU approves Chiesi’s triple combination asthma therapy Trimbow
European Commission has authorised treatment for uncontrolled asthma patients
UK bolsters Valneva COVID-19 vaccine deal
UK government has signed a deal for a further 40 million doses of vaccine
Bayer’s Xarelto approved in the UK
First oral factor Xa inhibitor approved for paediatric venous thromboembolism
Millions could benefit from genetic screening before prescribing, new research finds
Research led by the University of East Anglia in collaboration Boots UK and Leiden University
NHS has offered COVID-19 vaccine to all eligible care homes in England
Latest figures mark a ‘major milestone’ in vaccination drive
Kesimpta and Vazkepa among latest CHMP recommendations
Bumper meeting saw 13 new medicines recommended for approval
EU authorisation for AstraZeneca’s COVID-19 vaccine
Jab authorised for use in individuals aged 18 years and older
EMA begins review of GBT’s sickle cell treatment Oxbryta
GBT is aiming for the approval of Oxbryta to treat haemolytic anaemia in patients with sickle cell disease
Valneva completes recruitment for Phase I/II COVID-19 vaccine study
Speciality vaccine company has also started production of vaccine candidate
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early trials
Datopotamab deruxtecan and Enhertu were evaluated in non-small cell lung cancer patients
Novavax COVID-19 vaccine found to be 89.3% effective in UK trial
Meanwhile, Phase IIb results from South Africa trial demonstrated 60% efficacy
